An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
← catalyst calendarNCT05841537 · readout ≤ 712 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1,019actual
Sites
154
Countries
Austria, Canada, France +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-06-09 | actual | When the study began enrolling |
| Primary completion | Jul 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2023-05-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Crohn's Disease
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants with Clinical Remission among Participants with Clinical Response at Month 3
measured At Month 12
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed